Crossover Clinical Trials: When the Same Participant Receives More Than One Treatment

In most clinical trials, each participant is assigned to one treatment group at the start and stays in that group until the study ends. Crossover clinical trials operate on a different principle. The same participant receives two or more treatments in a planned sequence, with a structured rest period between them. This design lets researchers compare treatments using the same person as the reference point, rather than relying entirely on differences between separate groups.

The crossover design is far from universal. It works well for certain types of conditions and treatments, and poorly for others. Understanding how it works, when it is chosen, and what participation involves makes the structure easier to recognize when it appears in a study description.

What Is a Crossover Clinical Trial?

A crossover clinical trial is a randomized study in which each participant receives more than one treatment in a predetermined order. Like other randomized trials, crossover studies can include a placebo arm (an inactive control treatment used for comparison) and can be double-blinded, meaning neither the participant nor the research team knows which treatment is being given at any specific time.

The defining feature is the sequence. Instead of being placed into a single treatment group for the entire trial, a crossover participant moves from one treatment to another according to the study protocol. The order is randomized, so some participants receive Treatment A first and Treatment B second, while others receive the same treatments in the reverse order. Researchers measure the same outcomes after each treatment phase and then compare the results.

For a broader overview of how clinical trials are structured in general, see Clinical Trials Explained: Simple Guide for Beginners.

How the Crossover Design Works

To picture how the design works in practice, it helps to start with the simplest version: a trial that compares two treatments using what researchers call the AB/BA design.

Participants are randomly divided into two groups. Group 1 receives Treatment A for a defined period, then Treatment B. Group 2 receives Treatment B first and Treatment A second. Between the two treatments, every participant goes through a wash-out period: a span of time when no study treatment is given. The wash-out is intended to let the effects of the first treatment subside, so the second treatment is evaluated on a baseline that resembles the participant's starting state.

Consider a study comparing two migraine medications, Drug A and Drug B. A research team might assign participants with chronic migraine to one of two sequences. Half would take Drug A for four weeks, then take no study medication for four weeks, then take Drug B for four weeks. The other half would follow the same schedule in the order B, wash-out, A. The team would measure migraine frequency and severity after each treatment period for every participant.

The AB/BA model extends to three or more treatments. A three-treatment study might use ABC, CAB, and BCA sequences across different participant groups, each separated by wash-out periods. The same logic applies: every participant experiences every treatment, just in a different order.

Crossover trials are one of several specialized designs that researchers choose depending on the question they want to answer. For a comparison of two other distinct approaches, see What Is the Difference Between Pragmatic and Explanatory Clinical Trials?

Why Researchers Use This Design

The most significant advantage of the crossover design is that each participant serves as their own control. In statistics, this is called a within-subject comparison. Every measurement on Treatment A is paired with a measurement on Treatment B from the same person. Differences caused by individual factors such as age, weight, diet, baseline symptom severity, or medical history are largely controlled for, because both measurements come from the same body.

This has two important consequences. First, a crossover study can detect a difference between treatments using a smaller sample size than a traditional parallel-group trial. A standard randomized controlled trial typically requires participants split between two completely separate groups; a crossover trial can answer a similar question with roughly half as many participants, because each one contributes data on both treatments. Second, the design increases statistical power, which is the ability of a study to detect a real difference between treatments when one exists.

These efficiency gains matter most in conditions where the eligible participant pool is limited or where recruitment is difficult.

For context on how clinical trials use other design approaches to answer different research questions, see Phase 0 Clinical Trials: What They Are and Why They Exist.

When the Crossover Design Fits, and When It Does Not

A crossover trial is not suitable for every clinical question. The design works best for chronic conditions in which symptoms recur or fluctuate, treatment effects are reversible, and the underlying disease state stays relatively stable over the study period. Common examples include migraine and hot flashes (also called hot flushes), where symptoms come and go but the condition itself does not change rapidly.

Several scenarios call for a different design:

• Curative treatments or treatments with long-lasting effects
• Acute or self-resolving conditions
• Unstable or progressive diseases
• Situations where withholding an essential treatment would raise ethical concerns

The first issue is treatment durability. If a treatment is curative or has long-lasting effects, the crossover structure breaks down. The entire approach depends on the participant returning to a comparable baseline before the next treatment. If Treatment A's effects persist into the wash-out period, the measurement of Treatment B is contaminated by leftover effects of A.

The second is whether the condition resolves on its own. A trial for short-term pain after a sprained ankle, for instance, would not fit the design, because the outcome would change regardless of which treatment was given.

The third is disease stability. If the condition is unstable or progressive, the design introduces additional variability. Changes in the disease itself between treatment periods make it difficult to attribute results to the treatment rather than to disease progression.

The fourth is ethics. For a serious condition where one treatment is essential to a participant's health, switching the participant off that treatment during a wash-out period may not be acceptable. Type 2 diabetes is a frequently cited example: withholding glucose-lowering medication during a wash-out could put participants at risk. In such cases, researchers either avoid the crossover design or modify it so that essential baseline medications continue throughout the study.

Eligibility criteria for crossover trials often reflect these constraints, which can make them more selective than standard parallel-group trials. For more on why trial eligibility requirements can feel restrictive, see Eligibility Explained: Why Not Everyone Qualifies for a Trial.

What Participants Should Know About Crossover Trials

Participation in a crossover trial usually involves a longer total time commitment than a parallel-group trial of comparable size. Instead of being on one treatment for a fixed period, a crossover participant goes through at least two active treatment phases plus a wash-out interval between them. The full duration can range from days to many months, depending on the condition and protocol. More visits, more symptom tracking, and longer engagement with the research team are typical.

The wash-out period itself can require attention. Depending on the protocol, participants may need to stop the study treatment entirely during this interval. Some studies allow continued use of baseline medications for safety reasons (the diabetes example above is one such case). Participants should expect detailed instructions from the study team about exactly what to do, and what to avoid, during the wash-out.

Carry-over effects are the most discussed limitation of the design. Even with a planned wash-out period, a previous treatment can leave residual effects on the body or on symptom patterns. These effects can be difficult to detect and harder to quantify. To minimize them, some pharmacologic studies use dose de-escalation, where the dose of an active treatment is gradually reduced before the wash-out begins. This is intended to make the transition cleaner.

To support consistent and transparent reporting of these trials, the international Consolidated Standards of Reporting Trials (CONSORT) initiative published a dedicated extension for crossover designs in 2019. The CONSORT extension is a 25-item checklist that guides how the design, conduct, and results of a crossover trial should be described in scientific publications. Adherence to the extension helps clinicians and patients evaluate whether the trial's findings are reliable.

DecenTrialz is a clinical trial recruitment and pre-screening platform. Its role is to help connect people who may be eligible for a trial with the research teams running those studies, including trials that use crossover designs. Decisions about enrollment, informed consent, eligibility determinations, and treatment are made by the authorized research site and study team, not by the platform.

For a crossover study in particular, the longer commitment and the wash-out structure are points worth discussing with the study team before agreeing to participate. A useful starting point is reviewing common questions to raise during that conversation; see Top Questions to Ask Before Joining a Clinical Study.

If you are exploring whether a clinical trial may be a fit for your situation, visit decentrialz.com to learn more.